Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection

Infection and Immunity

Volumn 71, Issue 7, 2003, Pages 3988-3994

  Ferraz Coelho, Eduardo Antonio ^a   Pereira Tavares, Carlos Alberto ^a   Amorim Carvalho, Fernando Aécio ^a,d   Chaves, Karina Figueiredo ^a   Teixeira, Kadima Nayara ^a   Rodrigues, Rafaela Chitarra ^a   Charest, Hugues ^e   Matlashewski, Greg ^c   Gazzinelli, Ricardo Tostes ^a,b   Fernandes, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c MCGILL UNIVERSITY   (Canada)

^d FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^e Universidade Federal do Piauí ^*

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; LACK ANTIGEN; LEISHMANIA DONOVANI A2 ANTIGEN; LEISHMANIA VACCINE; PARASITE ANTIGEN; PROTEIN KINASE C; PROTOZOAL VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INFECTION CONTROL; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TROPICAL DISEASE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINES, SYNTHETIC;

EID: 0038309759     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.7.3988-3994.2003     Document Type: Article

References (38)

1. Afonso, L. C., and P. Scott. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952-2959.
2. Barral, A., D. Pedral-Sampaio, H. Momen, D. McMahon-Pratt, A. R. De Jesus, R. Almeida, R. Badaró, M. Barral-Neto, E. M. Carvalho, W. D. Johnson, and G. Grimaldi, Jr. 1991. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg. 44:536-546.
3. Bottrel, R. L. A., W. O. Dutra, F. A. Martins, B. Gontijo, E. Carvalho, M. Barral-Netto, A. Barral, R. P. Almeida, W. Mayrink, R. Locksley, and K. J. Gollob. 2001. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble leishmania antigen in human cutaneous leishmaniasis. Infect. Immun. 69:3232-3239.
4. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
5. Carvalho, F. A. A., H. Charest, C. A. P. Tavares, G. Matlashewski, E. P. Valente, A. Rabello, R. T. Gazzinelli, and A. P. Fernandes. 2002. Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn. Microbiol. Infect. Dis. 43:289-295.
6. Charest, H., and G. Matlashewski. 1994. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol. Cell. Biol. 14:2975-2984.
7. Courret, N., E. Prina, E. Mougneau, E. M. Saraiva, D. L. Sacks, N. Glaichenhaus, and J. C. Antonie. 1999. Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. Eur. J. Immunol. 29:762-773.
8. Faria, A. M., S. M. Ficker, E. Speziali, J. S. Menezes, B. Stransky, B. A. Verdolin, W. M. Lahmann, V. S. Rodrigues, and N. M. Vaz. 1998. Aging and immunoglobulin isotype patterns in oral tolerance. Braz. J. Med. Biol. Res. 31:35-48.
9. Fernandes, A. P., E. C. Herrera, W. Mayrink, R. T. Gazzinelli, W. Y. Liu, C. A. Costa, C. A. P. Tavares, M. N. Melo, M. S. M. Michalick, R. Gentz, and E. Nascimento. 1997. Immune responses induced by a Leishmania (Leishmania) amazonensis recombinant antigen in mice and lymphocytes from vaccinated subjects. Rev. Inst. Med. Trop. Sao Paulo 39:70-78.
10. Fernandes, A. P., F. A. A. Carvalho, C. A. P. Tavares, H. C. Santiago, G. A. Castro, W. L. Tafuri, L. A. M. Ferreira, and R. T. Gazzinelli. 2001. Combined interleukin-12 and topical chemotherapy for established leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. J. Infect. Dis. 183:1646-1652.
11. Ferreira-Pinto, K. C., A. L. Miranda-Vilela, C. Anacleto, A. P. S. M. Fernandes, M. C. B. Abdo, M. L. Petrillo-Peixoto, and E. S. A. Moreira. 1996. Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines. Can. J. Microbiol. 42:944-949.
12. Ghedin, E., H. Charest, and G. Matlashewski. 1998. A2 rel: a constitutively expressed Leishmania gene linked to an amastigote-stage-specific gene. Mol. Biochem. Parasitol. 93:23-29.
13. Ghosh, A., S. Labrecque, and G. Matlashewski. 2001. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response., Vaccine 19:3169-3178.
14. Ghosh, A., W. W. Zhang, and G. Matlashewski. 2002. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20:59-66.
15. Grimaldi, G., Jr., R. B. Tesh, and D. McMahon-Pratt. 1989. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am. J. Trop. Med. Hyg. 41:687-725.
16. Grimaldi, G., Jr., and R. B. Tesh. 1993. Leishmaniasis of the New World: current concepts and implications for future research. Clin. Microbiol. Rev. 6:230-250.
17. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
18. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409-1415.
19. + T cells resulting in a state of unresponsiveness to IL-12. J. Immunol. 161:6156-6163.
20. Ji, J., J. Sun, H. Qi, and L. Soong. 2002. Analysis of T helper cell responses during infection with Leishmania amazonensis. Am. J. Trop. Med. Hyg. 66:338-345.
21. Jones, D. E., L. U. Buxbaum, and P. Scott. 2000. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J. Immunol. 165:364-372.
22. Jones, D. E., M. R. Ackermann, U. Wille, C. A. Hunter, and P. Scott. 2002. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70:2151-2158.
23. Julia, V., M. Rassoulzadegan, and N. Glaichenhaus. 1996. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274:421-423.
24. + T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice. Infect. Immun. 67:3641-3644.
25. Kaye, P. M., A. J. Curry, and J. M. Balckwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine genetically controlled vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763-2770.
26. Kima, P. E., S. L. Constant, L. Hannum, M. Colmenares, K. S. Lee, A. M. Haberman, M. J. Shlomchik, and D. McMahon-Pratt. 2000. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 191:1063-1067.
27. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6:541-549.
28. Lehmann, J., K. H. Enssle, I. Lehmann, A. Emmendorff, and M. L. Lohman-Matthes. 2000. The capacity to produce IFN-gamma rather than the presence of IL-4 determines resistance and the degree of susceptibility to Leishmania donovani infection in mice. J. Interferon Cytokine Res. 20:63-77.
29. Leon, L. L., G. M. C. Machado, L. E. Carvalho Paes, and G. Grimaldi, Jr. 1990. Antigenic differences of Leishmania amazonensis isolates causing diffuse cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 84:678-680.
30. q syngeneic high and low antibody responder mice (Biozzi mice). Scand. J. Immunol. 48:144-151.
31. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
32. Mendez, S., Y. Belkaid, R. A. Seder, and D. Sacks. 2002. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
33. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppola, Z. E. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
34. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
35. + T cells in pathogenesis associated with Leishmania amazonensis infection. J. Immunol. 158:5374-5383.
36. Torrentera, F. A., N. Glaichenhaus, J. D. Lanan, and Y. Carlier. 2001. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana. Infect. Immun. 69:617-621.
37. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.
38. Zhang, W. W., H. Charest, E. Ghedin, and G. Matlashewski. 1996. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol. Biochem. Parasitol. 78:79-90.